艾尔巴韦格拉瑞韦与索磷布韦维帕他韦治疗丙型肝炎的成本-效果分析

Cost-Effectiveness Analysis of Elbasvir/Grazoprevir and Sofosbuvir/Velpatasvir in the Treatment of Hepatitis C

目的评价艾尔巴韦格拉瑞韦片(EBR/GZR)与索磷布韦维帕他韦片(SOF/VEL)治疗中国人群基因1型(GT1慢性丙型肝炎(CHC)的经济学。方法构建Markov模型估计两种方案的患者终身成本和所获得效用,进行成本-效果分析,并对基础分析结果进行敏感性分析。结果相比SOF/VEL,EBR/GZR对于无肝硬化患者(13.844 2 QALYs vs. 13.782 9QALYs, 82 199.8元vs. 94 470.4元)和肝硬化患者(12.668 7 QALYs vs. 12.557 1 QALYs, 230 026.4元vs. 242 784.5元)均效用更高、成本更低,具有经济学优势。结论对于中国GT 1型CHC患者,不论是否合并肝硬化,基于真实世界研究中的SVR,EBR/GZR方案相对于SOF/VEL方案的经济学更优。

Objectives To conduct cost-effectiveness analysis of elbasvir/grazoprevir(EBR/GZR)versus sofosbuvir/velpatasvir(SOF/VEL)in Chinese hepatitis C patients with genotype 1 infection.Methods Markov cohort state-transition model was performed to conduct cost-effectiveness analysis.Sensitivity analysis was conducted based on base-case analysis.Results EBR/GZR showed higher QALYs and lower costs for noncirrhotic patients(13.8442 QALYs vs 13.7829 QALYs,82 199.8 RMB vs94 470.4 RMB)and cirrhotic patients(12.6687 QALYs vs 12.5571 QALYs,230 026.4 RMB vs 242 784.5 RMB)compared with SOF/VEL.Conclusions EBR/GZR regimen was more economic in noncirrhotic and cirrhotic patients compared with SOF/VEL for Chinese patients with hepatitis C virus genotype 1 infection when using the real-world SVR.